null

null

null

null

null

null

null

null

null

0.00x Total Debt / Equity (Conservative)

Moderate; NeuroPace carries ~$50M debt; 200bps rate rise increases annual interest ~$1M, manageable but pressures thin operating margins

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Semiconductor components (Taiwan/TSMC ecosystem) and precision medical device subassemblers concentrated in Asia-Pacific represent primary chokepoints

Minimal international revenue (<5% of total); negligible sovereign currency devaluation exposure; company is predominantly US-focused

~95% US revenue; minimal EUR/GBP/JPY exposure; currency devaluation risk effectively immaterial to near-term financials

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; custom ASIC and implantable neurostimulator components likely sourced from 1-2 specialized suppliers representing non-substitutable critical inputs

Cloud disruption risk is low-moderate; core RNS System device data platform could face 60-90 day migration disruption but patient therapy delivery is hardware-dependent

Medical device hardware company with emerging data/software layer; cloud termination affects MyDayTM app and remote monitoring but not core implant therapy

Low API coupling risk; proprietary closed-loop system with minimal third-party API dependencies; patient data ecosystem is internally controlled

Fails Howey Test; revenue from FDA-regulated medical device sales and implant procedures; no investment contract, profit-sharing, or speculative instrument involved

Very High

Moderate HIPAA exposure primary; CCPA applicable to California patients; GDPR immaterial given negligible EU operations; PHI handling requires robust BAA compliance

Low; niche market with small revenue base (~$60M); RNS System faces competition from LivaNova VNS and DBS therapies; no dominant market position triggers scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~70% transactional (device implant sales), ~30% recurring (replacement generators, remote monitoring subscriptions); recurring component growing slowly

Hardware implant sale + periodic pulse generator replacement cycle (5-7 years) + patient data management platform subscription emerging as secondary vector

ASP ~$35,000-$40,000 per RNS System; pricing protected by CPT reimbursement codes; insurance coverage gaps in Medicaid represent stress vulnerability

Moderate-high; only FDA-approved closed-loop responsive neurostimulation device; reimbursement-anchored pricing limits both upside and downside flexibility

77.2% Gross Margin (Premium (>60%))

No free-rider problem; implanted device creates permanent patient dependency; physician loyalty risk exists if competitor achieves superior clinical outcomes

Headcount-sublinear for device scaling; manufacturing scales with contract partners; however, field clinical specialist headcount scales near-linearly with new implant volume

Moderate marginal cost; 2x revenue requires ~1.5x headcount given field clinical support model; gross margins ~65% suggest meaningful operating leverage potential

Not applicable; NeuroPace operates direct sales model, not a franchise structure

At 10x scale, CAC likely compresses as epilepsy center penetration deepens; current ~500 epilepsy centers addressable; TAM constraints emerge before CAC becomes problematic

Weak network effects; larger patient dataset improves seizure detection algorithms creating data moat, but physician adoption is not network-dependent

AI displacement risk low near-term; RNS algorithm improvement is AI-enhanced not AI-replaced; FDA regulatory pathway protects against rapid AI-native competitor entry

Tier 2 moderate resilience; drug-resistant epilepsy is serious chronic condition but elective implant timing deferred during economic stress; reimbursement dependency adds risk

Comprehensive epilepsy centers and neurosurgeons treating drug-resistant focal epilepsy patients; ~500 US centers represent primary institutional customer base

Drug-resistant epilepsy patients (estimated 1.2M US addressable); secondary payer customers include Medicare, Medicaid, and commercial insurers controlling reimbursement access

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.3% CapEx / Revenue (Low-CapEx Asset-Light)

0001528287

NPCE